Filtered By:
Management: Medicaid
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 217 results found since Jan 2013.
Colorado Medicaid will get $5.5 million of EpiPen settlement
Colorado ’s Medicaid program will get a piece of the $465 million U.S. Justice Department settlement with the makers of the EpiPen.
The settlement follows a lawsuit accusing the pharmaceutical company of overcharging the government’s Medicaid program for the EpiPens, a hand-held device used for emergenc y allergy treatments.
Colorado will receive $5.5 million of that settlement with Mylan Inc. and Mylan Specialty L.P. – the companies accused of knowingly underpaying rebates owed to the Medicaid…
Source: bizjournals.com Health Care:Physician Practices headlines - August 29, 2017 Category: American Health Authors: Monica Mendoza Source Type: news
Pa. to get $8.3M in Mylan EpiPen settlement
Pennsylvania will receive $8.3 million from the settlement between Mylan NV and the U.S. Department of Justice over EpiPen pricing.
The settlement, announced Thursday, involves the federal government's claims that it was overcharged for the anti-allergy treatment under Medicaid programs. Mylan did not acknowledge wrongdoing but agreed to the $456 million settlement.
"As we said when we announced the settlement last year, brin ging closure to this matter is the right course of action for Mylan and…
Source: bizjournals.com Health Care News Headlines - August 18, 2017 Category: Health Management Authors: Paul J. Gough Source Type: news
EpiPen maker settles federal claims for $465M a year after Sanofi filed suit
Mylan NV will pay $465 million fine to settle claims brought by the U.S. Justice Department that it overcharged the government for its emergency allergy drug, EpiPen.
The U.S. Attorney’s Office in Massachusetts announced the agreement on Thursday, saying it had violated the False Claims Act “by knowingly misclassifying EpiPen, a branded epinephrine auto-injector drug, as a generic drug to avoid paying rebates owed to Medicaid.”
French drug company Sanofi , the parent company of the state’s…
Source: bizjournals.com Health Care:Physician Practices headlines - August 17, 2017 Category: American Health Authors: Don Seiffert Source Type: news
Mylan inks $465m settlement with DOJ over EpiPen Medicaid classification
Mylan (NSDQ:MYL) said today that it inked a $465 million deal with U.S. Dept. of Justice to settle claims that it misclassified its EpiPen allergy auto-injector device with the Medicaid Drug Rebate Program.
In October last year, The Centers for Medicare & Medicaid Services said that Mylan had been overcharging Medicaid for its EpiPen device for years, despite being warned that it should have paid bigger rebates.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan inks $465m settlement with DOJ over EpiPen Medicaid classification appeared first on MassDevice.
Source: Mass Device - August 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Pharmaceuticals Wall Street Beat Centers for Medicare and Medicaid Services (CMS) Mylan Source Type: news
Disparities in sinonasal squamous cell carcinoma short ‐ and long‐term outcomes: Analysis from the national cancer database
ConclusionsSociodemographic and economic differences in outcomes of patients with sinonasal SCC cancer exist. An understanding of these differences may help minimize disparities in oncologic treatment.
Level of Evidence2c. Laryngoscope, 2017
Source: The Laryngoscope - August 16, 2017 Category: ENT & OMF Authors: Ryan M. Carey, Arjun K. Parasher, Alan D. Workman, Carol H. Yan, Jordan T. Glicksman, Jinbo Chen, James N. Palmer, Nithin D. Adappa, Jason G. Newman, Jason A Brant Tags: Allergy/Rhinology Source Type: research
Emergency department use for acute rhinosinusitis: Insurance dependent for children and adults
ConclusionWith respect to absolute numbers of visits, patients with Medicaid or no insurance use less care overall for uncomplicated ARS than do privately insured patients. Medicaid is associated with ED presentation for ARS for pediatric and adult visits. Self‐pay insurance status is strongly associated with ED presentation for adult and pediatric visits, and is significantly more common for children. These results suggest limitations in primary care access for uncomplicated ARS based on insurance status, particularly for uninsured pediatric patients.
Level of Evidence4. Laryngoscope, 2017
Source: The Laryngoscope - July 21, 2017 Category: ENT & OMF Authors: Regan W. Bergmark, Stacey L. Ishman, Katie M. Phillips, Michael J. Cunningham, Ahmad R. Sedaghat Tags: Allergy/Rhinology Source Type: research
Medicaid Enrollees Are Satisfied With Their Health Care
Enrollees rate their overall health care at 7.9, on average, on a scale of 1 to 10
Source: The Doctors Lounge - Psychiatry - July 12, 2017 Category: Psychiatry Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nephrology, Neurology, Nursing, Oncology, Ophthalmology, Orthopedics, ENT, Source Type: news
Firm urges shareholders to vote against Mylan board nominees
Shareholder advisory firm ISS issued a report today urging its clients to vote against 10 of Mylan‘s (NSDQ:MYL) board members and executive pay packages, including chief executive Heather Bresch and chairman Robert Coury.
The recommendation comes after a group of influential investors, including the New York City and State pension funds, encouraged other shareholders to vote against 6 board members and Coury.
ISS echoed the pension funds’ concerns, writing that the board mismanaged the widespread criticism around Mylan’s pricey EpiPen allergy auto-injector. The company is now the subject of numerous investigations i...
Source: Mass Device - June 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Mylan Source Type: news
Mylan May Have Overcharged U.S. For EpiPen By $1.27 Billion
By Michael Erman
NEW YORK (Reuters) - The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.
The amount is nearly three times a proposed settlement that the company announced in October.
The analysis on the EpiPen payments, which was conducted by the Department of Health and Human Services’ Office of Inspector General, was released by Republican Senator Chuck Grassley.
“Mylan and the Obama Administration reportedly were close to settling the overpayment...
Source: Healthy Living - The Huffington Post - June 1, 2017 Category: Consumer Health News Source Type: news
Industry relationships are associated with performing a greater number of sinus balloon dilation procedures
ConclusionThere is an association between receiving money from industry and the frequency with which otolaryngologists employ BD. Although our analysis demonstrates an association, these results in no way imply causation. Further analysis exploring the reasons for this association may be necessary.
Source: International Forum of Allergy and Rhinology - June 1, 2017 Category: Allergy & Immunology Authors: Jean Anderson Eloy, Peter F. Svider, Michael Bobian, Richard J. Harvey, Stacey T. Gray, Soly Baredes, Adam J. Folbe Tags: ORIGINAL ARTICLE Source Type: research
Report: Mylan may have overcharged US by $1.3B for EpiPen
Mylan (NSDQ:MYL) shares dipped slightly in mid-afternoon trading today after Sen. Chuck Grassley’s (R-Iowa) office released a Health and Human Services estimate claiming that taxpayers overpaid by as much as $1.27 billion for Mylan’s EpiPen device from 2006 to 2016.
The charges stem from Mylan’s decision to classify the emergency allergy auto-injector as a generic, instead of a branded product under the Medicaid Drug Rebate Program. Misclassifying the device allowed the company to pay the government a 13% rebate instead of a 23% rebate. The Centers for Medicare and Medicaid Services repeatedly warned Mylan that the...
Source: Mass Device - May 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Wall Street Beat Centers for Medicare and Medicaid Services (CMS) Mylan Source Type: news
Outpatient Wait Times Are Longer for Medicaid Recipients
Researchers suggest lag time might be due to providers having larger caseloads
Source: The Doctors Lounge - Psychiatry - May 11, 2017 Category: Psychiatry Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Nephrology, Neurology, Oncology, Ophthalmology, Orthopedics, ENT, Pediatrics, Psychiatry, Pulmonology, Rheumat Source Type: news
